| Today's Big NewsJun 7, 2023 |
|
Montgomery County, MD, is a thriving innovation hub for the life sciences industry. Be Next and learn how companies are making their mark in the immunology capital next to the nation’s capital. Learn more. 
|
|
| By Max Bayer Back in January, Moderna set a planned mpox vaccine on the back burner as the immediate outbreak waned, but now the shot has slid into the priority lane, with entry to the clinic likely a “month or so” away, according to a top vaccine developer and strategist at the company. |
|
|
|
| San Diego, CA |  |
|
|
By Gabrielle Masson Venture Capital has long been a man’s game. But the rules are changing. |
By Max Bayer Caribou Biosciences doesn't want to follow the leader as its cell therapy rival backs off to focus on relapsed patients with lymphoma. Instead, CEO Rachel Haurwitz, Ph.D., says the CRISPR-focused company is looking a few plays ahead. |
By Gabrielle Masson Astellas is busy. Very busy. With three oncology approvals expected in the next year—two of which are label expansion approvals and one entirely new treatment—it's enough to add a few extra gray hairs. |
By James Waldron FibroGen has now extended its clinical woes into a second month. After a phase 3 fail last month for Evrenzo dashed any remaining hopes of getting the oral anemia drug to market in the U.S., the biotech’s Duchenne muscular dystrophy candidate has now flunked a late-stage study. |
By Nick Paul Taylor Bayer is teaming up with the biotech behind the delivery of Comirnaty and Onpattro. The agreement allows the German drugmaker to use Acuitas Therapeutics’ lipid nanoparticle delivery technology to get its in vivo gene editing candidates to the liver. |
By Helen Floersh The largest-ever series A for a preclinical cardiovascular biotech will fund a fresh approach in the space—one that takes a hint from oncology and autoimmune disease |
By Nick Paul Taylor Alvogen has secured a low-risk shot at the treatment-resistant suicidal bipolar depression market. The deal gives the drugmaker the license to NRx Pharmaceuticals’ NRX-101—and it will only make the initial $10 million cash payment upon seeing positive data from a phase 2b/3 clinical trial of the candidate. |
By Kevin Dunleavy Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. At the BIO International Convention, Biogen CEO Chris Viehbacher registered severe criticism of the IRA and said his company was considering filing its own lawsuit. |
By Andrea Park Abiomed has begun a recall of several hundred of its Impella heart pumps after receiving nearly 200 complaints, and the FDA this week gave it a Class I rating, indicating a heightened risk of injury or death. |
By Paige Minemyer A federal appeals court held a brief hearing Tuesday afternoon to hear from attorneys on both sides as it decides whether to lift a nationwide freeze on a lower court's ruling that struck down preventive care protections in the Affordable Care Act. |
Fierce podcasts Don't miss an episode |
| 'Podnosis': Will price transparency move the needle on rising healthcare prices and Q1 financial trends |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Save $500 when you Register before June 19th! 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
